Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients

Inclusion Criteria:

• Age >= 18 years

• Women with a diagnosis of breast cancer who are being treated with curative intent,with the one exception being women who are receiving CDK4/6 inhibitors (thesepatients being allowed to have more advanced disease)

• Provide informed consent

• Ability to complete questionnaire(s) by themselves or with assistance

• Filling into one of the 5 groups (understanding that groups will close once theycomplete their accrual goals of 30 patients)

• Willingness to complete questionnaires every 3 months

• Ability to complete the first questionnaire within 2 weeks of therapy initiation (for the four arms that are receiving adjuvant hormonal therapy)

• For patients starting tamoxifen or an aromatase inhibitor: within 2 weeks ofstarting tamoxifen or aromatase inhibitor

• For patients starting a CDK 4/6 inhibitor: within 2 weeks of starting the CDK 4/6 inhibitor (patients may have started an aromatase inhibitor at any timeprior to initiation of CDK 4/6 inhibitor).

Exclusion Criteria:

• Verbal baseline alopecia >= 2 on an 11 point scale (from none = 0 to severe = 10).The question to use for this item is: Please rate your hair thinning or loss on ascale from 0 to 10, with 0 being no hair loss and 10 being complete hair loss

• Planned receipt of chemotherapy or another cancer-directed therapy concurrently (e.g., everolimus, etc.; note that a CDK4/6 inhibitor is allowed within cohort 3)

• Prior use of endocrine therapy for breast cancer

• Receipt of chemotherapy over the previous 6 months